microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10

Yang, Hongju; Li, Qian; Niu, Jie; Li, Bai; Jiang, Dejun; Wan, Zhihua; Yang, Qingmei; Jiang, Fei; Wei, Ping; Bai, Shu

doi:10.18632/oncotarget.6458

Cited by 60 publications

(46 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant expression of 5 miRNAs reported in this study (miRNA-3615, miRNA-342, miRNA-339, miRNA-182, and miRNA-4485) has been previously reported in relation to liver cirrhosis or HCC malignancy (29) as well as some other cancers such as lung adenocarcinoma (30) , melanoma (31) , colorectal cancer (32) (33) , gastric cancer (34) (35) , intrahepatic cholangiocarcinoma (36) , colon cancer (37) , and breast cancer (38) (39) . Recently Wojcicka et al employed next generation sequencing to investigate the expression of microRNA in tissue samples of HBV/HCV infected with liver cirrhosis and HCC.…”

Section: Discussionsupporting

confidence: 76%

Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

Riazalhosseini

Mohamed

Apalasamy

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Hepatitis B virus (HBV) constitutes an important risk factor for cirrhosis and hepatocellular carcinoma (HCC). The link between circulating microRNAs and HBV has been previously reported, although not as a marker of liver disease progression in chronic hepatitis B (CHB). The aim of this study was to characterize miRNA expression profiles between CHB with and without cirrhosis or HCC. Methods: A total of 12 subjects were recruited in this study. We employed an Affymetrix Gene Chip miRNA 3.0 Array to provide universal miRNA coverage. We compared microRNA expression profiles between CHB with and without cirrhosis/HCC to discover possible prognostic markers associated with the progression of CHB. Results: Our results indicated 8 differently expressed microRNAs, of which miRNA-935, miRNA-342, miRNA-339, miRNA-4508, miRNA-3615, and miRNA-3200 were up-regulated, whereas miRNA-182 and miRNA-4485 were down-regulated in patients with CHB who progressed to cirrhosis/HCC as compared to those without progression. Conclusions: We demonstrated the differential expression of between patients with HBV without cirrhosis/HCC and those who had progressed to these more severe conditions. These miRNAs may serve as novel and non-invasive prognostic markers for early detection of CHB-infected patients who are at risk of progression to cirrhosis and/or HCC.

show abstract

Section: Discussionsupporting

confidence: 76%

Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

Riazalhosseini

Mohamed

Apalasamy

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Studies by Park et al showed Naa10 as required for doxorubicin NF-κB activation by its interaction with the receptor-interacting protein 1 (RIP1) [159]. Recently, NAA10 expression in colon cancer was found regulated by microRNAs, targeting NAA10 for degradation [160].…”

Section: Naa10 -A Tumor Suppressor?mentioning

confidence: 99%

The world of protein acetylation

Drazic

Myklebust

Ree

et al. 2016

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

659

532

View full text Add to dashboard Cite

Acetylation is one of the major post-translational protein modifications in the cell, with manifold effects on the protein level as well as on the metabolome level. The acetyl group, donated by the metabolite acetyl-coenzyme A, can be co- or post-translationally attached to either the α-amino group of the N-terminus of proteins or to the ε-amino group of lysine residues. These reactions are catalyzed by various N-terminal and lysine acetyltransferases. In case of lysine acetylation, the reaction is enzymatically reversible via tightly regulated and metabolism-dependent mechanisms. The interplay between acetylation and deacetylation is crucial for many important cellular processes. In recent years, our understanding of protein acetylation has increased significantly by global proteomics analyses and in depth functional studies. This review gives a general overview of protein acetylation and the respective acetyltransferases, and focuses on the regulation of metabolic processes and physiological consequences that come along with protein acetylation.

show abstract

“…miR-608 is a novel prognostic marker in carcinogenesis, its expression is dysregulated in various cancers (18)(19)(20)(21). A previous study by our group demonstrated that downregulation of B-cell lymphocyte xL (BCL-XL), the other major prototype of the anti-apoptotic bcl-2 gene, dysregulates various miRNAs in lung adenocarcinoma cell line A549, including miR-608.…”

Section: Introductionmentioning

confidence: 99%

miR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2

Othman

Nagoor

2017

International Journal of Oncology

View full text Add to dashboard Cite

Lung cancer remains a major health problem with a low 5-year survival rate of patients. Recent studies have shown that dysregulation of microRNAs (miRNAs) are prevalent in lung cancer and these aberrations play a significant role in the progression of tumour progression. In the present study, bioinformatics analyses was employed to predict potential miR-608 targets, which are associated with signaling pathways involved in cancer. Luciferase reporter assay identified AKT2 as a novel target of miR-608, and suppression of its protein levels was validated through western blot analysis. Zebrafish embryos were microinjected with cells transfected with miR-608 to elucidate the role of miR-608 in vivo, and immunostained with antibodies to detect activated caspase-3. We present the first evidence that miR-608 behaves as a tumour suppressor in A549 and SK-LU-1 cells through the regulation of AKT2, suggesting that selective targeting of AKT2 via miR-608 may be developed as a potential therapeutic strategy for miRNA-based non-small cell lung cancer (NSCLC) therapy.

show abstract

microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10

Cited by 60 publications

References 30 publications

Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

The world of protein acetylation

miR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2

Contact Info

Product

Resources

About